Why the study?
Despite advances in treatment, valvular heart disease remains underdiagnosed, identified late, undertreated, and lacks medications to prevent progression.
This review highlights significant gaps in the diagnosis and management of valvular heart disease, emphasizing the need for improved access to care and novel medical therapies to prevent disease progression.
Prepare for rising VHD burden in aging populations; leaves open optimal policy and resource responses to therapeutic advances.
Valvular heart disease (VHD) is the next epidemic in the cardiovascular field, affecting millions of people worldwide and having a major impact on health care systems. With aging of the population, the incidence and prevalence of VHD will continue to increase. However, VHD has not received the attention it deserves from both the public and policymakers. Despite important advances in the pathophysiology, natural history, management, and treatment of VHD including the development of transcatheter therapies, VHD remains underdiagnosed, identified late, and often undertreated with inequality in access to care and treatment options, and there is no medication that can prevent disease progression. The present review article discusses these gaps in the management of VHD and potential actions to undertake to improve the outcome of patients with VHD.
No takes yet. Share an insight, caveat, or question.
Messika‐Zeitoun et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: